NEWARK, DEL. -- Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, announced a majority investment by Curewell Capital (“Curewell”), a Los Angeles-based private equity firm focused on building industry-leading healthcare companies. Hui-Yin “Harry” Li, Ph.D., Founder and CEO of WPT, will retain a significant ownership stake and will continue to lead the business alongside the management team. The partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the U.S.

Founded in 2003, WPT has built extensive expertise across hundreds of novel drug substance programs, spanning complex synthesis, medicinal chemistry, scale-up, and GMP supply. The company offers comprehensive API development, analytical, and manufacturing solutions that seamlessly bridge from early discovery and clinical development through scale up and commercial supply.

Headquartered at its 54-acre campus in Delaware, WPT operates two adjacent state-of-the-art facilities with extensive cGMP manufacturing capabilities, including dedicated high potency API (HPAPI) suites, as well as registered starting material (RSM) support and R&D facility in Suzhou, China. The Delaware campus also includes substantial permitted greenfield space for future complex biopharmaceutical manufacturing expansion, positioning WPT as a strategic partner for biopharmaceutical innovators seeking dedicated U.S.-based capacity.

“Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies, and we are committed to further expanding our capabilities and capacity to better serve our global biopharmaceutical partners,” said Dr. Li. “Wilmington PharmaTech is the ideal partner for innovators seeking to solve complex challenges in process R&D and manufacturing, enhance cost-efficiency, and accelerate the speed of the production process to bring new therapies to patients faster.”

“We are thrilled to partner with Dr. Li and his outstanding team, who have built an exceptional organization with deep scientific expertise and a strong reputation for excellence within the pharma science community,” added Michael Dal Bello, Partner at Curewell Capital. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for specialized development capabilities and dependable, high-quality manufacturing capacity in the U.S.”

Potter Anderson served as legal advisor to Wilmington PharmaTech. Kirkland & Ellis served as legal advisor to Curewell Capital.